文献速递MDS 与骨髓增殖性肿瘤

骨髓增生异常综合征患者心血管死亡的风险与时机

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2017-10-18

该研究基于美国国家癌症研究所的监测、流行病学和最终结果数据库,纳入2001至2011年间21 372例有已知死因的成人骨髓增生异常综合征(MDS)患者,并与同州一般人群比较。结果显示MDS患者心血管病死亡率为每10万人年4613例,标化死亡比为2.21;在生存超过60个月的低危患者中,心血管原因死亡占比高于MDS本身。

要点

  • MDS患者心血管病死亡率为每10万人年4613例,标化死亡比2.21。
  • 24个月时归因于MDS或白血病的累积死亡率为23%,心血管病为8%。
  • 生存超过60个月的低危患者中,心血管原因死亡占30%,高于MDS本身的24%。

核心结论

  • MDS患者死于心血管原因的可能性高于一般人群。
  • 作者认为,针对MDS相关临床诊疗,尤其对低危疾病患者,可能需要干预心血管危险因素。

研究设计与样本

  • 基于美国国家癌症研究所监测、流行病学和最终结果数据库的队列研究,纳入2001至2011年间21 372例有已知死因的成人MDS患者,并与同州一般人群比较。
  • 将MDS组织学亚型分为低危、中危和高危疾病。
  • 主要结局为总生存率和向州登记处报告的主要死因。

主要发现

  • 心血管病死亡率为每10万人年4613例,年龄和性别调整的美国人群为每10万人年2091例(标化死亡比2.21)。
  • 24个月时归因于MDS或白血病的累积死亡率为23%,心血管病为8%。
  • 在60个月时仍存活者中,最终27%死于心血管病,29%死于MDS或白血病。
  • 生存超过60个月的低危疾病患者中,死于心血管原因者占30%(95%CI 26.7-33.2%),死于MDS本身者占24%(95%CI 21.4-27.5%)。

临床怎么用

  • 作者认为,针对MDS相关临床诊疗,尤其对低危疾病患者,可能需要干预心血管危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders associated with progression to leukemia and poor survival. Clonal hematopoiesis in people without an MDS diagnosis carries an increased risk of cardiovascular death. Many clonally restricted mutations are shared between patients with MDS and those with non-MDS clonal hematopoiesis; therefore, we evaluated the risk of cardiovascular death among patients with MDS. We evaluated adults with MDS in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute and compared them with the general population living in the same states. We grouped histological subtypes of MDS into lower-, intermediate-, and higher-risk disease. The primary outcomes were overall survival and primary cause of death (COD) as reported to state registries. A total of 21 372 patients with MDS between 2001 and 2011 died during follow-up with a known COD. The rate of death due to cardiovascular disease (CVD) was 4613 per 100 000 person-years, compared with 2091 in the age- and-sex-adjusted US population (standardized mortality ratio, 2.21). At 24 months, the cumulative incidence of death attributed to MDS or leukemia was 23% vs 8% for CVD. Among those alive at 60 months, 27% eventually died of CVD compared with 29% from MDS or leukemia; those with lower-risk disease who survived >60 months had more deaths attributed to cardiovascular causes (30%; 95% confidence interval [CI], 26.7-33.2%) than MDS itself (24%; 95% CI, 21.4-27.5%). Patients with MDS are more likely to die of cardiovascular causes than the general population. Modifying cardiovascular risk factors, especially among those with lower-risk disease, may be warranted for MDS-related clinical care.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Brunner AM, Blonquist TM, Hobbs GS, et al. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017. PMID: 29296849. doi:10.1182/bloodadvances.2017010165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。